Compare NextEra Energy, Inc. (NEE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs TG Therapeutics Inc — how do they compare? NextEra Energy, Inc. trades at $77.43 (market cap $161.39B), while TG Therapeutics Inc trades at $54.88 (market cap $8.16B). The key difference: NextEra Energy, Inc. is far larger — about 19.8× TG Therapeutics Inc's market cap, and NextEra Energy, Inc. pays a 3.22% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NextEra Energy, Inc. for 83 Days and TG Therapeutics Inc for 16 Days on average.
| NEE | TGTX | |
|---|---|---|
Market Cap | $161.39B | $8.16B |
Volume | 11,780,955 | 1,735,121 |
Sector | Utilities | Health |
52-Week High | $97.88 | $59.06 |
52-Week Low | $75.49 | $26.94 |
Typical Hold Time | 83 Days | 16 Days |
Enterprise Value | $268.72B | $8.37B |
Dividend Yield | 3.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $77.34, up 0.36% on the day, with a bearish technical signal but strong analyst support. The stock is near a 52-week low, with key support at $76. Recent earnings show mixed results, beating in Q1 and Q2 2026 but missing in Q4 2025. The company maintains robust profitability with a 32.4% net margin and is pursuing growth through projects like the $22.3 billion Project Star energy campus.
The outlook is cautiously optimistic, with a consensus price target of $96 offering 24% upside. Risks include high debt levels and interest rate sensitivity, but strong cash flow and a 66.7% buy rating from analysts suggest long-term value. Investors should weigh growth initiatives against macroeconomic headwinds.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
